<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833140</url>
  </required_header>
  <id_info>
    <org_study_id>2021P001506</org_study_id>
    <nct_id>NCT04833140</nct_id>
  </id_info>
  <brief_title>Estrogen Administration for the Treatment of NASH in Postmenopausal Women</brief_title>
  <official_title>Estrogen Administration for the Treatment of NASH in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite&#xD;
      this, the treatment options remain limited. Preclinical and preliminary clinical data suggest&#xD;
      that estrogen deficiency plays an important role in the pathology of steatosis, inflammation&#xD;
      and fibrosis in non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD.&#xD;
      Post-menopausal women are a growing population with particularly high risk of NASH due to&#xD;
      their lack of estrogen. This study will examine the effect of estradiol on hepatic fibrosis&#xD;
      and fat in post-menopausal women with NASH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver fibrosis</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction in degree of liver fibrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver fat</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction in amount of fat in the liver</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estradiol in the form of a transdermal patch 100 mcg daily (Vivelle-Dot generic).&#xD;
Women with an intact uterus will also receive progesterone (100 mg) in the form of a vaginal tablet (Endometrin, Ferring Pharmaceuticals, Inc.) inserted daily for endometrial protection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patch (containing no estradiol) Women with an intact uterus will also receive vaginal placebo capsules (containing no progesterone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol patch</intervention_name>
    <description>The patch will provide 100mcg of estradiol daily.</description>
    <arm_group_label>Estradiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo patch will contain no estradiol.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Postmenopausal women 45-70 years old&#xD;
&#xD;
          -  NASH by biopsy or NAFLD by imaging within 6 months of screen&#xD;
&#xD;
          -  Hepatitis C antibody and hepatitis B surface antigen negative&#xD;
&#xD;
          -  Negative mammogram within 1 year&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Heavy alcohol use&#xD;
&#xD;
          -  Use of NASH pharmacotherapies within 12 months of study entry&#xD;
&#xD;
          -  Known cirrhosis, stage 4 fibrosis on biopsy, or clinical evidence of cirrhosis or&#xD;
             portal hypertension on imaging or exam&#xD;
&#xD;
          -  Participation in NASH clinical trial within 6 months of study entry&#xD;
&#xD;
          -  Chronic use of corticosteroids, methotrexate, amiodarone, or tamoxifen within 6 months&#xD;
             of entry&#xD;
&#xD;
          -  Known diagnosis of chronic liver disease other than NAFLD or found on biopsy&#xD;
&#xD;
          -  Contraindication to liver biopsy including INR &gt; 1.5, platelets &lt; 50,000/mL, ascites,&#xD;
             chronic anticoagulation (other than aspirin), biliary obstruction, peritonitis,&#xD;
             inability to lie supine for 30 minutes&#xD;
&#xD;
          -  Hgb &lt; 10.0 g/dL or glomerular filtration rate &lt; 60 mL/min&#xD;
&#xD;
          -  Contraindications to estrogen therapy&#xD;
&#xD;
          -  Any vaginal bleeding, including spotting, within the last year&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Severe chronic illness&#xD;
&#xD;
          -  Use of estrogen or progesterone within a year of baseline visit&#xD;
&#xD;
          -  Routine MRI exclusion criteria such as the presence of a pacemaker or cerebral&#xD;
             aneurysm clip&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen K. Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachsuetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anu Gerweck, NP</last_name>
    <phone>617-724-1837</phone>
    <email>avgerweck@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 3, 2021</study_first_submitted>
  <study_first_submitted_qc>April 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Klahr Miller, MD</investigator_full_name>
    <investigator_title>Chief, Neuroendocrine Unit, Massachusetts General Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

